IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism

Hepatology

Volumn 61, Issue 5, 2015, Pages 1627-1642

  Yamada, Daisaku ^a   Rizvi, Sumera ^a   Razumilava, Nataliya ^a   Bronk, Steven F ^a   Davila, Jaime I ^a   Champion, Mia D ^b   Borad, Mitesh J ^b   Bezerra, Jorge A ^c   Chen, Xin ^d   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; INTERLEUKIN 33; INTERLEUKIN 6; MITOGENIC AGENT; PEPTIDES AND PROTEINS; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR SOX9; TRANSPOSASE; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; IL33 PROTEIN, MOUSE; INTERLEUKIN DERIVATIVE; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP PROTEIN, MOUSE;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT LIGATION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HEPATITIS; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN MODIFICATION; RNA SEQUENCE; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TRANSPOSON; WILD TYPE; ANIMAL; BILE DUCT TUMOR; BIOLOGICAL MODEL; C57BL MOUSE; GENETICS; INTRAHEPATIC BILE DUCT; PHYSIOLOGY; TUMOR CELL CULTURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; INTERLEUKIN-33; INTERLEUKIN-6; INTERLEUKINS; MALE; MICE; MICE, INBRED C57BL; MODELS, GENETIC; ONCOGENES; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR CELLS, CULTURED;

EID: 84928214400     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27687     Document Type: Article

References (32)

1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013;145:1215-1229.
2. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173-184.
3. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829-840.
4. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2012;9:44-54.
5. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States. Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009;136:1134-1144.
6. Ko KS, Peng J, Yang H. Animal models of cholangiocarcinoma. Curr Opin Gastroenterol 2013;29:312-318.
7. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010;19:491-505.
8. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005;128:2054-2065.
9. Menakongka A, Suthiphongchai T. Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. World J Gastroenterol 2010;16:713-722.
10. Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, et al. Activation of beta catenin and Yap1 in Human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology 2014;147:690-701.
11. Li J, Razumilava N, Gores GJ, Walters S, Mizuochi T, Mourya R, et al. Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest 2014;124:3241-3251.
12. Marvie P, Lisbonne M, L'Helgoualc'h A, Rauch M, Turlin B, Preisser L, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010;14:1726-1739.
13. Rizvi S, Mertens JC, Bronk SF, Hirsova P, Dai H, Roberts LR, et al. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem 2014;289:22835-22849.
14. Chen X, Calvisi DF. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol 2014;184:912-923.
15. Grubman SA, Perrone RD, Lee DW, Murray SL, Rogers LC, Wolkoff LI, et al. Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines. Am J Physiol 1994;266:G1060-G1070.
16. O'Hara SP, Splinter PL, Trussoni CE, Gajdos GB, Lineswala PN, LaRusso NF. Cholangiocyte N-Ras protein mediates lipopoly saccharide-induced interleukin 6 secretion and proliferation. J Biol Chem 2011;286:30352-30360.
17. Ishimura N, Bronk SF, Gores GJ. Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth. Am J Physiol Gastrointest Liver Physiol 2004;287:G88-G95.
18. Yahagi K, Ishii M, Kobayashi K, Ueno Y, Mano Y, Niitsuma H, et al. Primary culture of cholangiocytes from normal mouse liver. In vitro Cell Dev Biol Anim 1998;34:512-514.
19. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010;19:27-38.
20. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005;42:1329-1338.
21. Kalari KR, Nair AA, Bhavsar JD, O'Brien DR, Davila JI, Bockol MA, et al. MAP-RSeq: Mayo analysis pipeline for RNA sequencing. BMC Bioinformatics 2014;15:224.
22. Wang L, Wang S, Li W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 2012;28:2184-2185.
23. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009;25:1105-1111.
24. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009;10:R25.
25. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-140.
26. Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther 2008;7:2339-2347.
27. Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 2013;144:1530-1542.
28. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-124.
29. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012;122:2911-2915.
30. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 2013;155:384-396.
31. Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, et al. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int 2012;32:38-47.
32. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999;30:1128-1133.